

Olivia M Dong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8254311/publications.pdf>

Version: 2024-02-01

17
papers

169
citations

1163117

8
h-index

1125743

13
g-index

17
all docs

17
docs citations

17
times ranked

269
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of <i>CYP2C19</i> -guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 249-257.	4.0	3
2	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. <i>Value in Health</i> , 2022, 25, 582-594.	0.3	6
3	Are We Ready for a New Approach to Comparing Coverage and Reimbursement Policies for Medical Nutrition in Key Markets: An ISPOR Special Interest Group Report. <i>Value in Health</i> , 2022, 25, 677-684.	0.3	1
4	Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program. <i>Pharmacogenomics</i> , 2021, 22, 137-144.	1.3	16
5	ONE-YEAR COST-EFFECTIVENESS OF CYP2C19- GUIDED DE-ESCALATION AND ESCALATION OF P2Y12 INHIBITORS IN VETERANS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3416.	2.8	0
6	Using the Diffusion of Innovation Theory to Understand the Challenges and Opportunities to Advancing Use of Nutrigenetics in Clinical Practice. <i>Lifestyle Genomics</i> , 2021, 14, 1-5.	1.7	0
7	Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. <i>Journal of Personalized Medicine</i> , 2021, 11, 647.	2.5	13
8	A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. <i>Journal of Personalized Medicine</i> , 2021, 11, 1123.	2.5	7
9	Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. <i>Pharmacogenomics</i> , 2021, 22, 1121-1133.	1.3	5
10	Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. <i>Value in Health</i> , 2020, 23, 61-73.	0.3	30
11	Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. <i>Pharmacogenomics</i> , 2019, 20, 1005-1020.	1.3	9
12	Clinical pharmacogenetics: how do we ensure a favorable future for patients?. <i>Pharmacogenomics</i> , 2018, 19, 553-562.	1.3	5
13	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 6652.	2.1	4
14	Implementing Clinical Pharmacogenomics in the Classroom: Student Pharmacist Impressions of an Educational Intervention Including Personal Genotyping. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 115.	1.6	18
15	Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. <i>Pharmacogenomics</i> , 2018, 19, 771-782.	1.3	13
16	Advancing precision medicine in healthcare: addressing implementation challenges to increase pharmacogenetic testing in the clinical setting. <i>Physiological Genomics</i> , 2017, 49, 346-354.	2.3	8
17	<i>CYP2C19</i> -guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. <i>Pharmacogenomics</i> , 2017, 18, 1155-1166.	1.3	31